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Abstract
Biologic drugs are highly complex molecules produced by living cells through a multistep manufacturing
process. The key characteristics of these molecules, known as critical quality attributes (CQAs), can vary
based on post-translational modifications that occur in the cellular environment or during the manufacturing
process. The extent of the variation in each of the CQAs must be characterized for the originator molecule and
systematically matched as closely as possible by the biosimilar developer to ensure bio-similarity. The close
matching of the originator fingerprint is the foundation of the biosimilarity exercise, as the analytical tools
designed to measure differences at the molecular level are far more sensitive and specific than tools available
to physicians during clinical trials. Biosimilar development, therefore, has a greater focus on preclinical attri-
butes compared with the development of an original biological agent. As changes in CQAs can occur at
different stages of the manufacturing process, even small modifications to the process can alter biosimilar
attributes beyond the point of similarity and impact clinical effectiveness and safety. The manufacturer’s ability
to provide consistent production and quality control will greatly influence the acceptance of biosimilars. To this
end, preventing drift from the required specifications over time and avoiding the various implications brought
by product shortage will enhance biosimilar integration into daily practice. As most prescribers are not familiar
with this new drug development paradigm, educational programmes will be needed so that prescribers see
biosimilars as fully equivalent, efficacious and safe medicines when compared with originator products.
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Rheumatology key messages
. Variation in biologics is influenced by their manufacturing processes, which adds complexity to biosimilarity
development.
. Modern analytics enable the fingerprinting and replication of the critical attributes of a reference product.
. A well-controlled manufacturing process ensures that the biosimilar product consistently matches the originator
fingerprint.
Introduction
Biological therapies (biologics) have transformed the ap-
proach to the treatment of cancer and of several types of
immune-mediated inflammatory diseases, including in-
flammatory rheumatic disease [1, 2] and IBD [3].
Advanced biologics, such as glycosylated mAbs and
fusion proteins, have emerged as popular targets for the
development of therapeutic candidates because of their
high potency, their ability to bind to a wide array of mo-
lecular targets with high specificity, and their stability
[4, 5]. However, unlike small-molecule drugs, which are
one-dimensional and chemically defined molecular enti-
ties, biologics are much larger in size and have greater
structural complexity, including primary, secondary, ter-
tiary and, possibly, quaternary structures [6]. Their bio-
logic activity is notably defined by their structure [7] and
by the cell-based manufacturing process that is used to
produce them [6].
The complexity of a biologic can best be described by
the physical, chemical, biological or microbiological prop-
erties that define them [8, 9]. These properties are known
as quality attributes of the biologic, and each product can
have dozens of them. However, among the several quality
attributes of the product, only a subset of these have a
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direct impact on the efficacy or safety of the product, and
these are known as critical quality attributes (CQAs) [10].
Examples of the CQAs of an mAb that can impact clinical
activity are shown in Table 1 [1122]. CQAs must be rou-
tinely monitored and controlled within a specified limit or
range to ensure the desired product quality is achieved
during manufacturing [23]. This biological complexity
makes biologics more difficult to characterize, produce
and reproduce [6, 24, 25].
A biosimilar is a biopharmaceutical that has demon-
strated similar CQAs, biological function, clinical efficacy
and safety to that of an already licensed biologic reference
product [2629]. Importantly, biosimilars should not be
considered to be generic versions of the reference bio-
logic, because they are not identical. Indeed, molecules
of this complexity cannot be reproduced identically by the
manufacturers of either the biosimilar or the originator
product [6, 24, 30]. However, although not all attributes
of a biologic can ever be replicated exactly, the develop-
ment process for a biosimilar must focus on those quality
attributes that matter most; namely, those that can have
clinically relevant implications (i.e. the CQAs). Matching
the originator CQAs as closely as possible is the major
focus of the development of a robust biosimilar manufac-
turing process [6, 3133] Biosimilarity must first be proved
in an extensive analytical comparability exercise, system-
atically evaluating the quality and similarity of the bio-
similar product and the originator product across dozens
of physicochemical, biological and pharmacological
CQAs, before establishing equivalence in clinical efficacy
and safety [6, 27].
Given that the process defines the product, it is import-
ant that anyone intending to use a biosimilar understands
the biosimilar process development exercise and how a
robust manufacturing process can result in a highly similar
biosimilar molecule with consistent product quality. Here,
we provide a simple overview of the complex processes
behind biosimilar development, production scale-up,
manufacturing and quality control and highlight the
direct influence that these processes have on ensuring
that the clinically relevant attributes of the molecule are
maintained throughout the different steps of the manufac-
turing process and throughout the life cycle of the pro-
duct. The totality of the evidence needed to establish
biosimilarity and the associated process are detailed else-
where in this supplement (see [34]) and summarized de-
scriptively with the associated nuances here.
Biologics are inherently variable
The inherent variability of biologics makes them impos-
sible to replicate exactly. Their heterogeneity is influenced
both by biological processes inside the cells that are used
to express them and by the manufacturing process used
to produce them (see Fig. 1) [35]. Recombinant proteins
are produced by living cells, which can modify the protein
structure based on their growth environment. Through
several enzymatic processes, each cell expression
system imprints distinct post-translational modifications
(PTMs; for mAbs see Fig. 2), which may differ between
cell lines, between different clones derived from the
same parental cell line [6] and even between individual
proteins produced by the same cell (isoform micro-
heterogeneity).
The biochemical variability resulting from PTMs is inher-
ent to all biological therapies and can include glycosyla-
tion, phosphorylation, deamidation, methylation and
acetylation [36]. A typical mAb, for example, can have
millions of molecular variants based on potential PTMs
alone (Fig. 2) [37]. Several PTMs, such as glycosylation,
can have a direct impact on the clinical properties of
therapeutic proteins, potentially influencing their biologic
activity (potency), pharmacokinetics (PK), pharmaco-
dynamics (PD) or immunogenicity [38]. Glycosylation can
be considered the most complex PTM, and its potential
for clinically relevant impact and its susceptibility to
change based on process conditions make it extremely
challenging to control [39]. For example, the degree of
fucosylation and mannosylation can have a significant
impact on the effector function of a mAb [namely FcRIIIa
receptor binding and antibody-dependent cell cytotoxicity
(ADCC)], which plays a key role in triggering the killing of
disease cells bound by the therapeutic antibody by natural
killer cells [38, 40]. Likewise, the extent of terminal man-
nose or sialic acids can significantly alter the circulating
PK half-life of an antibody or a fusion protein, and the
presence of an a-Galactose epitope or N-
glycolylneuraminic sialic acid can elicit an immunogenic
response [38, 41].
Importantly, PTMs can result from naturally occurring
processes or can be introduced by the manufacturing
process used to produce biologic drugs [38]. For ex-
ample, the temperature in the bioreactor or the pH of
the final formulation can induce protein aggregation if
not properly controlled [35], which can be associated
with the immunogenicity of a biologic therapy [42, 43].
This potential for process variations to influence the im-
munogenicity of a compound poses some relevant clinical
concerns because there are no uniform standards for the
type, quantity and quality of evidence, and for guidance
on experimental design for immunogenicity assays or cri-
teria to compare the immunogenicity of biologic drugs
[44]. Furthermore, the sensitivity and specificity of
assays for testing immunogenic responses may still be
insufficient to predict rare cases of immunogenicity [43].
Other than glycosylation and aggregation, advanced bio-
logics can have dozens of additional CQAs, which are
defined as physical, chemical or biological properties
that should be within an appropriate limit, range or distri-
bution to ensure the desired product quality (i.e. CQA
ranges that ensure adequate efficacy and safety) [6,
4547]. As these attributes are influenced not only by
the cell-mediated PTMs, but also by the manufacturing
process [48, 49], it is important to understand how the
cell culture, purification, storage and other phases of the
manufacturing process can lead to further modifications
and can alter the distribution of product-related species in
the final product [42]. During the cell culture phase, indi-
vidual parameters, such as the temperature, pH and
www.rheumatology.oxfordjournals.org iv15
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FIG. 1 The biologics manufacturing process and the manufacturing steps that affect final characteristics of biologics
Information taken from Ahmed et al. [35].
FIG. 2 Potential mAb variants
An IgG antibody schematic is shown, with some potential structural variations resulting from post-translational modifi-
cations indicated by symbols. Each symbol is noted in the key with a list of variations. The number of variation sites in
each half-antibody  the number of possible variations at each site is in parenthesis. Not all possible variants are
described. For example, there are fucosylation variants in glycosylation that were not counted. If one assumes that these
variants are independent and if combinations are considered, each half-antibody has 2  6  4  4  5  5  2 = 9600
possible states. If one assumes that both halves of the antibody are independent, there are 96002 & 108 possible states.
Reprinted from Kozlowski S, Swann P. Current and future issues in the manufacturing and development of monoclonal
antibodies. Adv Drug Deliv Rev 2006;58(56):70722, [37], !2006, with permission from Elsevier.
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glucose concentration of the cell culture medium, the cell
culture duration and even the type of reactor used, have
the potential to alter the CQAs of the protein [37, 50].
Different steps of the purification phases can also alter
the oxidation, deamidation, fragmentation and aggrega-
tion of the biological molecules [50]. As each step of the
manufacturing process has multiple process parameters
that can alter the quality of the product, the manufacturing
process for biologics is highly challenging, with batch-to-
batch variability being the norm. For example, a recent
study found significant variation in the level of glycosyla-
tion in several batches of common originator biologic
therapies, such as infliximab, trastuzumab and bev-
acizumab; a phenomenon that can also be expected in
biosimilars [39]. As such, when developing a biosimilar,
the variability associated with the reference product
must be well understood, and the manufacturing process
for the biosimilar must be carefully controlled, as even
minor process alterations may have a potential irreparable
impact on the qualities of the biosimilar and its compar-
ability with the reference product [28, 30, 35, 42].
Biologic product quality changes resulting from process
variation may be unintended or intended. Unintended pro-
cess variation may occur owing to the impact of uncon-
trolled variables and can result in gradual changes over
time or in a sudden shift in a quality attribute, a process
called manufacturing drift [5153]. The source of the
change may not be well understood and may be an unin-
tended result of changes outside of the manufacturer’s
control, such as variability in raw material. Lack of control
or understanding of the process may result in an unusable
product. If the biosimilar does not meet the release or simi-
larity criteria, it creates the potential for a supply disruption
or drug recall; if several batches are affected, the potential
for a drug shortage increases [54]. In addition to normal
batch-to-batch variability and drift, additional changes in
product quality may be the result of intentional changes
made by the manufacturers of biological medicines to the
manufacturing process and can range from changes in
manufacturing sites to changes in suppliers or cell culture
media. In addition, changes to a manufacturing process
are sometimes made to introduce new technologies that
can improve productivity. This type of manufacturing evo-
lution has been observed in most, if not all, approved anti-
rheumatic biologics on the market in the European Union
(EU) today since their initial approval, with some having
had more than 50 approved changes [35, 51, 53, 5557].
In some cases, these changes have modified the quality of
the molecule, but the majority of post-approval manufac-
turing changes have been considered to be non-critical
because they are unlikely to have impacted the CQAs of
the product [56].
Preclinical analytical comparability as the
foundation
The development of new biologics emphasizes the role
of clinical trials because the goal of the development
process is to demonstrate de novo the riskbenefit
profile of the drug candidate. However, in biosimilar de-
velopment the reverse is true, because the aim of the
manufacturer is to demonstrate that the biosimilar is
highly similar to the reference product by demonstrating
that physicochemical and biological CQAs of the biosmi-
liar closely match those of the originator, to be able to
leverage the riskbenefit profile that has previously been
established by the manufacturer of the originator product
[6, 45, 46]. The European Medicines Agency (EMA) states
that similarity between the biosimilar and the originator
product should be established using the best possible
means [27]. In much the same way that it has relied
on analytical comparability studies to demonstrate that
two versions of the same originator product are highly
comparable after a change in the manufacturing process,
the EMA has concluded that similarity is best demon-
strated at the analytical level [27]. This is because,
based on their high-resolution potential and their ability
to assess individual molecular attributes quantitatively,
analytical methods are more sensitive than clinical trials
at detecting even small differences at the molecular level
[58]. Physicochemical and biological analytical tools
required for accurately mapping CQAs and demonstrating
comparability of the biosimilar with the reference biologic
(Fig. 3) have vastly improved over the past few years [45,
59]. These tools have much greater sensitivity, resolution
and throughput compared with those accessible to the
developers of the first generation of biologicals [42, 45,
59]. For example, the resolution potential of mass spec-
trometry has improved by a factor of more than 1 million in
the past three decades, implying that we are now able to
quantify differences in molecules at the parts-per-trillion
level [60]. As a consequence, the preclinical phase,
including the analytical comparability exercise, is where
the most effort is concentrated because this is where
most of the uncertainty regarding the similarity of two mol-
ecules is addressed and reduced (Fig. 4; also [34] in this
supplement).
The originator fingerprint: a framework
for biosimilar development
Demonstrating similarity first begins at the level of
the building block, or molecular attribute. Given that
advanced biologics can have many CQAs and that ori-
ginator biologics have a high degree of inherent variabil-
ity attributable to PTMs or to the manufacturing
process, the development of a biosimilar must begin
by thoroughly characterizing as many of the quality at-
tributes of the originator as possible and establishing
the range of variation for each attribute that is
deemed to be critical (i.e. CQAs) [61]. The analytical
characterization typically includes the assessment of
physicochemical attributes (which can include primary
and higher-order structure, purity and glycosylation)
and functional attributes [which shed light on the mol-
ecule’s mechanism of action (MOA) and intended biolo-
gical activity] [6]. The biological assays complement the
structural analysis by enabling determination of the
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potential impact of observed structural differences be-
tween the biosimilar and reference biologic on the effi-
cacy or safety of the product [45]. With the current
status of science, these in vitro tests are particularly
sensitive to detect differences between closely related
molecules [62]. Put together, all of the characterized
attributes and their corresponding ranges make up the
fingerprint of the originator product, which provides the
framework, or similarity goal posts, against which the
biosimilar is developed. The aim of biosimilar process
development is then to match this fingerprint, one
attribute at a time, ensuring that the biosimilar is reverse
engineered to similar specifications.
Defining the fingerprint of the originator biologic is an
extensive exercise that involves the upfront development
of highly sensitive state-of-the-art analytical methods to
measure the relevant CQAs and non-CQAs of the refer-
ence product systematically. In order to establish a range
that represents the expected variability of the originator
biologic, several lots of the originator biologic are
acquired and tested; the more lots that are analysed
during the development exercise, the more confidence
FIG. 4 Comparison of the developmental processes for a reference (originator) product and a biosimilar
FIG. 3 Comparability of the biosimilar with the originator attributes (fingerprint) during the biosimilar development
process
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the biosimilar developer will have in defining the limits of
similarity for each attribute. For example, during the de-
velopment of SB4, a biosimilar to etanercept, the com-
pany developed 61 state-of-the-art analytical methods
and tested 30 batches of EU-marketed originator and
more than 30 batches of US-marketed originator during
the biosimilar development process [11]. Likewise, during
the development of SB2, a biosimilar to infliximab, the
possible quality attributes of SB2 were compared with
more than 80 lots of EU- and US-marketed originator
product using more than 60 structural, physicochemical
and biological analyses [17]. The results of a subset of
these analyses, which demonstrated the similarity be-
tween SB2 and its originator, are shown in Table 2 [17].
Process development: a tougher chal-
lenge for biosimilars
Although the complexity of advanced biologics makes en-
gineering them extremely challenging, reverse engineering
an advanced biologic to match the originator fingerprint is
perhaps more challenging. This is because the develop-
ment of an originator biologic follows a linear sequence of
steps, performed over an average time frame of 58 years
[63, 64]. Importantly, the goal during originator process
development is to produce sufficient product with high
yield, while ensuring removal of process-related impurities
to safe levels, and not necessarily to ensure that the ori-
ginator molecule fits a constrained target range for all crit-
ical attributes [37]. To achieve this, the manufacturer first
develops a preliminary manufacturing process that results
in an initial version of the product that is not fully charac-
terized or deeply evaluated, yet appropriate for the early
non-clinical animal studies or first-in-human trials. The
CQAs of the new molecular entity are not fully defined
and, at that stage, also often not fully understood, as
was the case with infliximab, where insights into its
MOA in the treatment of IBD are only recently being
described through the work done by the biosimiliar devel-
opers [65]. Consequently, the relationship between the
molecular structure and the biological or clinical function
of the molecule has not been elucidated with all of the
required analytical tests. It is only after the initial clinical
trials that the originator fully develops the necessary ana-
lytical tests to characterize the product and finalizes the
manufacturing process and product quality profile of the
originator product. In this case, the fingerprint of the ori-
ginator is the end result and is controlled and defined by
the manufacturers of the originator product.
The development of the manufacturing process for a
biosimilar is much more complicated because the devel-
oper is faced with several constraints at the start of de-
velopment. First, the development exercise must start
with defining the originator fingerprint for dozens of quality
attributes in order to set limits on the potential variability of
the biosimilar. Second, as the manufacturing process for
the originator molecule is unknown to the biosimilar de-
veloper, a new process must be engineered to ensure that
the biosimilar matches the originator fingerprint as closely
as possible. This iterative process requires the cell culture
and purification process conditions to be adjusted con-
tinuously, while screening hundreds of new cell lines
during development until the fingerprint of the biosimilar
is guided into the range of similarity, one quality attribute
at a time [6, 45, 46]. The biosimilar candidate can only be
taken into confirmatory clinical trials once the molecule
has been thoroughly characterized, the process has
been well defined and the similarity of the two molecules
has been confirmed. This front-loading of analytical char-
acterization and process development ensures that there
should be little residual uncertainty, in that the molecules
will have similar clinical efficacy and safety because the
molecules have been demonstrated to be highly similar at
the molecular level, using the most sensitive analytical
methods available.
The analytical comparability exercise does not end
once the biosimilar candidate has been shown to meet
the similarity criteria. On the contrary, the similarity as-
sessment is an ongoing exercise that requires the biosi-
milar candidate to be assessed throughout the life cycle of
the product, from process development, through scale-up
and process validation and after any manufacturing pro-
cess changes are introduced. This ongoing analytical
comparability minimizes the risk that the product diverges
in a clinically meaningful way from the approved molecular
fingerprint.
The process defines the product: quality
by design, and achieving similarity
through target-directed process
engineering
The target-directed development of biologics and biosimi-
lars is known as quality by design (QbD) [66]. QbD is a
systematic risk-based approach to the development of a
product and the associated manufacturing processes that
relies on properly identifying a drug’s CQAs and defining
limits for each CQA based on its potential clinical impact
(e.g. the originator fingerprint). QbD applies principles of
quality risk management and differs from previous
approaches to process development in ensuring that
drug quality is built into every step of the product devel-
opment exercise rather than relying on the final testing of
the product as the only check for quality control [10]. QbD
achieves this through the implementation of process con-
trols and CQA limits at every step of the process, estab-
lishing a link between process parameters and their
impact on the quality of the product to ensure that the
end product meets the expected quality profile [67].
For a biosimiliar, the QbD approach relies on the upfront
definition of the originator fingerprint; a set of CQAs
whose functional and structural characteristics are most
relevant for the clinical outcomes of the reference product
[6, 68, 69]. Examples of the attributes that can form a
biologic’s fingerprint, and their potential relationship to a
clinical outcome, are shown in Table 1. The biosimilar
product profile is then systematically analysed against
the originator fingerprint throughout the development of
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the different phases of the manufacturing process, follow-
ing an extensive iterative process development exercise
that can involve thousands of experiments [10]. In all, the
product and process knowledge base must include an
understanding of the variability in raw materials, the rela-
tionship between process parameters and CQAs, and the
association between CQAs and the clinical characteristics
of the biosimilar [10].
Below, we provide an overview of the relevant steps in
the development of a biosimilar manufacturing process.
Step 1: cell line selection and engineering
One of the most crucial process development decisions
made during the development of a biosimilar is the choice
of cell line. The cell line is one of the key determinants of
the glycosylation patterns of biologicals, making the
choice of the mammalian expression host very important
in determining the final glycoform profile of the biosimilar
[41, 70]. For example, Chinese hamster ovary-based cell
lines are the most popular for the development of biolo-
gical drugs because they generally produce similar glyco-
sylation patterns to humans and have several advantages,
including their ability to grow in suspension, their high
specific yield and their stability to changes in pH and
oxygen [71]. However, Chinese hamster ovary cell lines
are unable to produce certain human glycans, while con-
versely also being able to produce certain glycans that are
not typical in humans (such as a-gal and
N-glycolylneuraminic), which could lead to increased im-
munogenicity [71]. Cell line engineering can also result in
the over- or underexpression of certain enzymes that are
responsible for the regulation of certain glycoforms. For
example, ADCC can be improved dramatically by the
overexpression of N-acetylglucosaminyltransferase III to
increase the amount of bisecting N-acetylglucosamine
forms, or by decreasing the fucose on antibodies [72].
The careful genetic engineering and monitoring of the
cell lines is important during cell line selection, which is
a process that can involve the screening of hundreds to
thousands of clones to achieve the appropriate analytical
fingerprint [72].
Step 2: cell culture process development
The cell culture process involves thawing a vial of frozen
cells from a cell bank. The vial is inoculated into shake
flasks to increase the cell density, and the cells are then
grown in serial sub-cultivations until the target production
scale is reached. The cells are maintained in growth media
and are provided with the required nutrients and additives
to ensure the viability of the cells. Slightly altering the cell
culture conditions can have a significant impact on several
CQAs, including glycosylation and impurity profiles, and
must be carefully controlled [39]. To attain the quality
target product profile, several parameters are optimized
during process development, involving the performance
of hundreds of small-scale experiments using sound stat-
istical procedures [73]. Parameters investigated during the
cell culture process development include the following:
oxygen levels, lactate production, temperature, pH,
osmolality and duration [72]. These parameters are con-
tinuously monitored during the scale-up of the process to
ensure consistent performance as the cell culture volume
is increased until the ultimate production scale is reached
(e.g. 15 00020 000 l).
Step 3: purification process optimization to guide
CQAs into similarity range
Once the cell culture phase is completed, a purification
process is used to recover the target protein, while remov-
ing unwanted impurities, including adventitious viruses,
host cell proteins and DNA, aggregates and endotoxins
[74]. As the target biosimilar is typically excreted into the
cell culture fluid by the mammalian cell, the recovery
process begins by removing the cellular debris through
centrifugation and filtration. The cell metabolism that
expresses the desired protein also generates several un-
desired product variants and impurities, so the purification
process is designed to purify the target biosimilar while
removing process impurities and additives that could po-
tentially be harmful to patients (e.g. immunogenic). In add-
ition, for biosimilars, the purification process must also
fine-tune the biosimilarity profile of the molecule, by tar-
geting the removal or enrichment of certain product-
related attributes (isoforms, glycans, charged variants,
etc.), in order to achieve the target originator biologic fin-
gerprint. The purification process primarily relies on
column chromatography and filtration to remove these
undesired impurities, by exploiting the interaction be-
tween chemically functionalized resins or filters and the
biochemical and/or physical properties of the proteins
[74]. For example, cation or anion exchange chromatog-
raphy can be used to separate positively (acidic) or nega-
tively (basic) charged isoforms of the biosimilar resulting
from C-terminal lysine heterogeneity [5, 75]. Likewise,
hydrophobic interaction chromatography can be used to
modify levels of misfolded and aggregated species, as
these product variants are typically more hydrophobic
than the correctly folded monomeric form of the protein
[76]. As with the development of the cell culture process,
several hundred sound statistical procedures are typically
performed during process development to characterize
how each operational parameter (e.g. pH, conductivity,
binding capacity or flow rate) can impact the CQAs of
the biosimilar and to define process controls that ensure
a consistent product, batch after batch, following scale-
up and routine manufacturing.
Step 4: achieving a stable formulation
After the product is purified, it is concentrated and formu-
lated using ultrafiltration and diafiltration. The goal of the
concentration step is to ensure that the product is de-
livered at a concentration that enables dose optimization
given the route of administration. For example, although
s.c. administration is often a preferred route of adminis-
tration for certain medications, a high-concentration for-
mulation must be used to minimize the injection volume
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[74]. However, advanced biologics, such as mAbs and
fusion proteins, have a tendency to aggregate or degrade
during the manufacturing process or during storage and
transportation, which can impact the batch-to-batch vari-
ability, efficacy or immunogenicity of the product [77].
Moreover, many human mAbs display poor biophysical
properties, such as low stability and a propensity to ag-
gregate, which may trigger immune responses [77]. The
product formulation is a crucial element of minimizing the
propensity of a product to degrade and maximizing its
shelf life. The development of a stable formulation step
involves the optimization of buffer conditions, including
pH, ionic strength, and the inclusion of excipients and
stabilizers in varying amounts [77]. The product is typically
subject to a myriad of solutions while exposing it to phys-
ical (e.g. agitation) or thermodynamic stress (e.g. tem-
perature, freezethaw) over extended periods of time;
the product is then assessed for chemical, colloidal and
conformational stability [78]. The final presentation (liquid,
frozen liquid or lyophilisate) will be dependent on the sta-
bility of the product in the form (ready to use); although a
liquid presentation is typically preferred, in some cases
the product may need to be frozen during storage or
may be lyophilized to minimize chemical degradation
[79]. Lyophilized forms have the disadvantage of add-
itional costs associated with development, manufacture
and testing and the need for diluents for reconstitution,
although they may reduce the number of resupply batches
that may be required owing to the superior stability of the
lyophilized form [79]. In cases where freezing is required, a
cryoprotectant (such as sucrose) is typically added to
minimize cryoprecipitation or aggregation resulting from
cryoconcentration [79].
Manufacturing controls ensure similarity
after scale-up and post-approval
The manufacturing process for biologics is lengthy and
complex, often involving many discrete unit operations
and activities. Each step can have several input variables
and, from start to finish, the manufacturing process in-
volves simultaneously controlling dozens of input param-
eters while performing quality control checks throughout
to ensure that the product meets precise allowable limits
at each phase. Changes to the manufacturing process
may also occur by regulatory request, by scaling up pro-
duction and fine-tuning process efficiency to improve
product quality and yield [9, 68], introducing process
drift or shifting over time [53, 80] (Fig. 5). As a result, this
manufacturing complexity can negatively impact batch-
to-batch consistency and patient safety if each parameter
is not properly monitored and controlled during large-
scale manufacturing [6]. Rigorous life-cycle management
and manufacturing quality control that follow the interna-
tional pharmaceutical industry standards for comparability
after manufacturing process alterations are fundamental
for maintaining the biosimilar CQAs within acceptable
ranges of variation [54, 68]. Adherence to these guidelines
may also avoid concerns about immunogenicity, product
recall and supply shortage after approval is granted [54,
68]. These process controls and guidelines, along with
stringent pharmacovigilance programmes to track and ac-
curately assess immunogenicity and adverse events after
approval [43, 81], minimize the risk to the patient and are
mandated by the EMA for any medicine, including bio-
similars [28, 82].
By helping to ensure consistency in product quality,
these process control guidelines also help to ensure the
continuity of product supply, which is a key consideration
in healthcare provision [8385]. A negative shift in product
quality is frequently a consequence of low-cost manufac-
turing, ageing manufacturing plants, contamination and
lack of good contracting practice [54]. Lack of sufficient
manufacturing capacity or poor inventory practices can
turn a quality issue into a disruption of supply and a po-
tential drug shortage [54] if the manufacturer is unable to
overcome a lost lot (or lots) by increasing production.
These situations can lead to forced or uncontrolled
switching of treatment regimens for non-medical reasons,
and could increase healthcare costs by forcing a switch to
an originator drug or otherwise delaying a switch to a
more affordable biosimilar [54, 8688]. Treatment switch-
ing, in particular, should instead be managed adequately
through proper patientphysician education, stakeholder
alignment and monitoring post-switch to minimize the po-
tential for differences in patient-reported outcomes and
prevent discontinuation for non-medical reasons (e.g. no-
cebo effects) [89, 90]. It is therefore important that both
biosimilars and reference products are produced in state-
of-the-art and specialized facilities that follow high-
standard manufacturing guidelines and QbD principles
[54]. Such facilities also ensure that a battery of rigorous
automated in-process controls is implemented to monitor
the biosimilar analytical fingerprint and batch-to-batch vari-
ability and to ensure that changes to the manufacturing
process take place in real time [61], allowing for prompt
assessment and troubleshooting of production drift (Fig.
4). This enables the product quality aspects to be adjusted
so as to fall consistently within those of the reference prod-
uct range and, as a consequence, it can prevent quality
disruption, batch failure and subsequent product shortage
[61]. This is an important principle, because acceptance of
biosimilars into daily clinical practice can be hindered by
clinicians’ reluctance to prescribe these agents in light of
potential supply disruptions and product shortage, an oc-
currence that has been reported ever more frequently with
a variety of medicines [8, 54, 88, 91]. Supply shortage re-
flecting manufacturing issues, as previously described, can
be avoided by adopting a shortage mitigation plan [84, 85],
involving effective management of drug inventory, active
management of raw materials and maintenance of multi-
site manufacturing capabilities, ensuring robust and secure
distribution networks and instigating a rapid response to
supply interruption signals (Table 3) [93]. Bearing in mind
the technical challenges in developing and producing a
biosimilar that matches all the CQAs of the reference prod-
uct, the ultimate decision to prescribe a biosimilar instead
of its reference biologic or the choice between biosimilars
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must take into consideration the manufacturer’s experi-
ence, record of consistent manufacturing, proven capacity
and stable supply chain [93].
Discussion
Biologic drugs are highly complex molecules that are pro-
duced by living cells through a multistep procedure. These
complex molecules have dozens of CQAs that can vary
based on the extent of the PTMs that occur in the cellular
environment or during the manufacturing process. Each
step of the manufacturing process can also impart vari-
ations to the CQAs. The extent of the variation in each of
the CQAs must be characterized for the originator mol-
ecule and must be systematically matched as closely as
possible by the biosimilar developer. The close matching
of the originator fingerprint is the foundation of the bio-
similar exercise, as the analytical tools designed to meas-
ure differences at the molecular level are far more
sensitive and specific than tools available to physicians
FIG. 5 Example of an automated, real-time, quality control using multivariate batch process modelling
(A) Normal growth. (B) Slow growth. Data from several historical batches are used to correlate parameter levels with
product quality, using multivariate modelling techniques, such as principal component analysis (PCA). Of the dozens of
parameter inputs, those that strongly correlate with product quality are summarized by a single output (principal com-
ponent), which describes a large portion of the potential variation in product quality. Historical data are also used to define
acceptable limits for each parameter.
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during clinical trials [58]. If two molecules are confirmed to
be highly similar at the building block level, there should
be little uncertainty that these molecules will have equiva-
lent clinical efficacy and safety.
Based on the superior ability of the preclinical analytical
evaluation to measure molecular and physical differences
between two products, it forms the foundation of the to-
tality of the evidence required to demonstrate that a bio-
similar is highly similar to the reference product.
The additional sources of evidence in a biosimilar devel-
opment programme are designed to address any remain-
ing uncertainty that may not be addressed by the pre-
clinical phase, and include potential non-clinical animal
studies, a phase I PK equivalence study, and a phase
III clinical efficacy and safety equivalence study (see [34]
in this supplement). The regulations for the development of
a typical biosimilar require that only a single phase
III clinical trial is performed in the most sensitive clinical
indication with a sensitive, reproducible end point.
However, extrapolation to other indications is not taken
for granted, even if the biosimilar demonstrated clinical
equivalence in the phase III trial; the reduced requirement
for phase III clinical data creates a potential void in evi-
dence related to the other indications in which the biologic
may be indicated. For extrapolation to be granted, the ap-
plicant must address this void by substantiating that the
biosimilar shares the same MOA involved in each of the
indications as the reference product [94]. The same MOA
is not always shared by all of the approved indications for
the reference product and, in some cases, the MOA for a
given indication is not known. If the MOAs are known, they
are best probed at the preclinical analytical level because
highly sensitive methods can be developed to measure
each CQA that could be associated with the different
MOAs. For example, to allow for extrapolation of the bio-
similar infliximab CT-P13 from RA (studied in the phase III
trial) to the inflammatory bowel indications (not studied in
pivotal trials), additional preclinical and clinical documenta-
tion was produced to show that the biosimilar did not only
bind to TNF-a, but also had ADCC [95] activity, which may
play an additional role in treatment of IBD [65]. In those
cases where the MOA is not known, additional evidence
must be provided beyond the preclinical data and the
single phase III trial, such as additional PD studies or
phase III studies [96]. An advantage of biosimilar mAbs is
that the predominant MOA is usually known; therefore, a
preclinical in vitro comparison of the biosimilar and the ref-
erence product binding to the target antigen is the primary
demonstration of similar MOA [58].
Changes in CQAs can occur at different stages of the
manufacturing process, requiring a deep understanding of
the molecule and the manufacturing process. This reflects
the complexity that characterizes each stage [50, 68, 80],
be it the biosimilar molecule glycosylation pattern that is
linked to the cell line used or its immunogenicity, which
can be associated, for example, with the purification pro-
cess and storage conditions [42]. Even small modifica-
tions to this process can alter the biosimilar attributes
beyond the point of similarity and thereby impact on clin-
ical effectiveness and safety [6, 38]. The manufacturer’s
ability to provide consistent production and quality con-
trol, prevent drift from the required specifications over
time and avoid the various implications brought by prod-
uct shortage will greatly influence the acceptance of bio-
similars and their integration into daily practice.
If well developed and demonstrated to have an equiva-
lent quality and clinical profile to their originator counter-
parts, biosimilars have the potential to transform healthcare
by helping to improve access to biologic therapies to
underserved populations, while also creating meaningful
savings in healthcare expenditures. However, as most
prescribers at this moment in time are not familiar with
this new drug development paradigm, educational
programmes to explain the essentials, as set out in this
paper, will be needed so that prescribers are able to gain
confidence in the stringency involved in the development,
manufacturing and approval of biosimilars as fully equiva-
lent efficacious and safe medicines, and to provide all
stakeholders (regulators, payers, prescribers and patients
alike) with an objective set of considerations that should
be weighed (preclinical quality of the product, clinical data
and manufacturer trustworthiness) when considering the
use of biosimilars. Moreover, as several biosimilars of a
given product become available, understanding these
concepts can help clinicians to make well-informed deci-
sions when selecting a biosimiliar and avoid potential pit-
falls related to the quality of the biosimilars and the
consistency of the manufacturers producing them.
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